Shenzhen BGI Genomics Co., Ltd.
2025 Annual Board of Directors Work Report
In 2025, the Board of Directors of Shenzhen BGI Genomics Co., Ltd. (hereinafter referred to as the "Company") strictly followed the "Company Law of the People's Republic of China" (hereinafter referred to as the "Company Law"), the "Securities Law of the People's Republic of China" (hereinafter referred to as the "Securities Law"), the "Guiding Opinions of the Shenzhen Stock Exchange on the Standard Operation of Listed Companies on the ChiNext Market" (hereinafter referred to as the "ChiNext Norms") and other laws and regulations, as well as the "Articles of Association" and "Board of Directors Meeting Rules" and other relevant regulations. The Board diligently performed its duties, diligently fulfilled its responsibilities, conscientiously implemented all resolutions of the shareholders' meeting, continuously improved the company's corporate governance structure, enhanced the company's standardized operation level, and ensured the company's sustainable, stable, and healthy development. The main work of the Board of Directors in 2025 is reported as follows:
I. Overall Business Operations in 2025
Adhering to the mission of "Gene Technology Benefits Humankind," the Company deeply practices the inclusive and precise prevention concept of "prevention is greater than treatment, and it is accessible to everyone." In 2025, the Company actively responded to the complex market environment, relying on its independent platform and big data advantages, driving product upgrades through technological innovation, accelerating global market expansion, and leading the innovative development of genomics with new models, new ideas, new technologies, and new scenarios. At the same time, through continuous deepening of lean management, optimizing operational efficiency and cost control, it has boosted quality and efficiency, promoting the company's high-quality and sustainable development.
In 2025, the Company achieved an operating revenue of 3,705.3850 million yuan, a year-on-year decrease of 4.18%; the net profit attributable to shareholders of the listed company was -61,665.51 million yuan, a year-on-year decrease in loss of 31.69%. For specific business performance, please refer to the Company's "2025 Annual Report": "Chapter III Management Discussion and Analysis" - "IV. Main Business Analysis."
II. Board of Directors' Performance in 2025
(I) Convening of Board of Directors Meetings
During the reporting period, the Company's Board of Directors held 4 meetings, reviewing 31 proposals. The meeting content involved major matters such as periodic reports, profit distribution, bank credit, fundraising for investment and use, related party transactions, guarantees, restricted stock vesting and price adjustments, and comprehensive revision of company systems. Through the full discussion and prudent decision-making of the Company's Board of Directors, the smooth progress of the Company's various business activities was ensured. During the reporting period, the procedures for convening, holding, and voting at the Board of Directors meetings complied with relevant laws and regulations. All directors personally attended the meetings, with no absences. All directors voted in favor of the proposals submitted to the Board of Directors for deliberation, and the resolutions were legal and valid. The specific situation is as follows: